As regards metabolic derangements in familial hypercholesterolemia, Fredrick son (1960) has made a detailed discussion and summarized that possible causes were: (1) alteration in rate of synthesis of cholesterol, (2) alteration in rate of degradation of cholesterol, (3) abnormality in the plasma transport system, or (4) abnormality in intestinal absorption or synthesis. The results of Harlan et al.'s experimental study did not provide any evidence which allowed for a choice between these possible mechanisms (Harlan et al. 1966 ).
In 1959, Gee et al. (1959) investigated the incorporation of labelled acetate into the plasma cholesterol of a patient with familial hypercholesterolemic xanthomatosis and concluded that in this patient the biosynthesis of free cholesterol and its turnover rate were greatly increased, although the rate of esterification was normal.
The purpose of the present paper is to report two cases of familial hyper cholesterolemia, with a marked increase in the in vivo and in vitro incorporation of labelled acetate or mevalonic acid into cholesterol.
REPORT OF CASES
Patient (1) . N.Y., a six-year-old boy, was admitted to our clinic on October 16, 1967 , with a complaint of shortness of stature.
The parents were living and healthy and not consanguineous. The patient had an elder brother, being 8 years old and healthy. The patient was born at full term after an uneventful pregnancy and delivery with birth weight of 2,680 g. given 4 g of cholesterol per day orally for four days. One hour after, the radioactive acetate was injected intravenously. In the two patients as well as in four controls, there were no significant effects of cholesterol loading on the in vivo incorporation of the radioactive acetate into serum cholesterol (cf. Table 3, TABLE 3 . In vivo incorporation of acetate-1-14C into serum cholesterol, Two patients with hypercholesterolemia and four controls were kept on an ordinary diet. After an oral dose of 4 g of cholesterol per day for 4 days acetate-1-14C was injected intravenously * Hours after an intravenous injection of radioactive acetate .
and Fig. 2 ). Our results were in agreement with the results by other investigators (Taylor et al. 1965; Chevallier 1967; Pauliger and Shipp 1965) , indicating an absence of negative feedback control of cholesterol synthesis in vivo in man (adult) and older children. Fujiwara et al. (1965) reported that there was a negative feedback control of the in vivo cholesterol synthesis in early infancy. It may be assumed, therefore, that feedback control mechanism in cholesterol metabolism is different among early infancy, older children, and adults.
2. In vitro incorporation of acetate-3H and mevalonie acid-114C into cholesterol in the liver: A slight increase in the incorporation of acetate-3H into free and ester cholesterol was observed in the liver homogenate of the patient (2). Incorporation of mevalonic acid-2-14C into cholesterol was significantly increased in the patient (2) (cf. Table 4 ). These findings may also suggest a more rapid conversion of mevalonic acid to cholesterol or a higher cholesterogenesis in this disorder than in controls.
3. In vitro incorporation of acetate-3H or mevalonic acid-2-14C into cholesterol by skin, adipose tissue, leukocytes, and bone marrow cells: Incorporation of acetate 3H and mevalonic acid -2-14C into free cholesterol by skin slices from the patient (2) was slightly increased as compared with that in controls. In adipose tissue of the patient (2), incorporation of acetate-3H into free cholesterol was also increased about 2 to 3 times as much as that of controls (cf. Table 5 ). In cases with leukocytes or bone marrow cells, no differences were observed in acetate or mevalonate incorporation into cholesterol between controls and the patient (2) (cf. Table 5 ). These results indicate that biosynthesis of cholesterol in skin, adipose tissues, bone marrow cells, and leukocytes are not so much involved in the elevation of serum cholesterol and that a possibly rapid conversion of mevalonic acid to cholesterol in the liver is responsible for hypercholesterolemia in this patient (2) (cf. Fig. 3 ). 
